Tag: drug discovery

New Drug Combination Redefines First-Line Treatment for Advanced Urothelial Cancer

July 1, 2025

“Recent developments have introduced promising therapies, notably the combination of enfortumab vedotin with pembrolizumab, which is now recommended as the first-line therapy following the EV-302 trial results.” BUFFALO, NY -… read more

Figure 7: ER stress signaling plays an important role in mediating GZ17-6.02/bortezomib lethality

Oncotarget

GZ17-6.02 With Proteasome Inhibitors Kills Multiple Myeloma Cells

March 6, 2024

“We believe that developing GZ17-6.02 as a novel multiple myeloma agent potentially opens up a multitude of novel opportunities to develop therapeutic approaches which will prolong patient survival.” BUFFALO, NY-… read more

Figure 1: A typical drug discovery and development strategy.

Oncotarget

Drug Discovery in Academia; Dumping in the Publication Landfill?

February 5, 2024

“[...] fruitful efforts to bring more drugs from bench to bedside could only be possible if we do not leave them ‘midway’!” BUFFALO, NY- February 5, 2024 – A new… read more

Figure 7: Immunological effect of Nerofe and DOX: CT26 murine model showing the immunological effect of Nerofe, DOX, and their combined treatment.

Oncotarget

Transformation of Immunosuppressive mtKRAS Tumors Into Immunostimulatory Tumors by Nerofe and Doxorubicin

July 5, 2023

“[...] we demonstrated that the combination of Nerofe and DOX exerts a synergistic effect during mCRC treatment [...]” BUFFALO, NY- July 5, 2023 – A new research paper was published… read more

Oncotarget

DPDT Anticancer Activity in Human Colon Cancer HCT116 Cells

June 26, 2023

“Altogether, our results show that DPDT preferentially targets HCT116 colon cancer cells likely through DNA topoisomerase I poisoning.” BUFFALO, NY- June 26, 2023 – A new research paper was published… read more

Figure 2: Kaplan–Meier curve for estimated median DOR in the DLBCL combined cohort (response-evaluable population).

Oncotarget

Oncotarget | Mivavotinib for Relapsed/Refractory B-cell Lymphoma (Updated)

February 1, 2023

“The current analysis provides updated results for these lymphoma patients with extended follow-up.” Listen to an audio version of this press release BUFFALO, NY- February 1, 2023 – A new… read more

Oncotarget

Oncotarget | CUDC907 Promotes Apoptosis of NF2 Schwannoma Cells

July 26, 2022

“CUDC907 has cytotoxic activity in NF2 schwannoma models and primary VS cells and is a candidate for clinical trials.” Listen to an audio version of this press release BUFFALO, NY-… read more

Oncotarget

Oncotarget | Continuous Treatment With Abemaciclib Leads to Sustained and Efficient Inhibition of Breast Cancer Cell Proliferation

July 6, 2022

“These preclinical results support the unique efficacy and safety profile of abemaciclib observed in clinical trials.” Listen to an audio version of this press release BUFFALO, NY- July 6, 2022… read more